Safety and tolerability of combined treatment with moclobemide and SSRIs: a preliminary study of 19 patients

Hawley, Christopher J.; Ratnam, S.; Pattinson, H.; Quick, Silvio; Echlin, D.

doi:10.1177/026988119601000311

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irreversible MAO inhibitors, such as tranylcypromine, can cause severe serotonin syndrome even when used alone (Boyer and Shannon, 2005 ). Reversible MAO-A inhibitors have also been associated with serotonin syndrome (Hawley et al, 1996a , b ; Mason et al, 2000 ). Moclobemide causes serotonin syndrome at a higher percentage (approximately 50%) when used with other serotonergic agents, including selective serotonin reuptake inhibitors and serotonin–noradrenaline reuptake inhibitor (Isbister et al, 2003 ).…”

Section: Introductionmentioning

confidence: 99%

Potential Roles of microRNAs in the Regulation of Monoamine Oxidase A in the Brain

Higuchi

Soga

Parhar

2018

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression. However, MAO-A inhibitors, which directly acts on MAO-A protein, have limited use due to their adverse effects. microRNAs (miRNAs) are 18–22 nucleotide long, small non-coding RNAs, which have recently emerged as regulators of protein levels that could potentially be new therapeutic targets for psychiatric disorders. This review article aims to discuss the current status of the treatment for depression with MAO-A inhibitors and the regulatory factors of MAO-A. Further, the review also proposes possible regulatory mechanisms of MAO-A by miRNAs, which leads to better understanding of the pathology of depressive disorders and their potential use as therapeutic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Potential Roles of microRNAs in the Regulation of Monoamine Oxidase A in the Brain

Higuchi

Soga

Parhar

2018

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…4 The recently introduced selective serotonin reuptake inhibiting (SSRIs) antidepressants are effective and generally safe drugs. Some authors [5][6][7][8] recommend their combination with MAO inhibitors in therapy-resistant depression, but the risks of developing a serotonin syndrome in this situation are considered high. [9][10][11] Serotonin syndromes have been described after combination of MAO inhibitors with the SSRIs sertraline, 12,13 fluoxetine, 14,15 citalopram 16 and with the serotonergic antidepressant clomipramine.…”

Section: Introductionmentioning

confidence: 99%

In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations

et al. 2002

View full text Add to dashboard Cite

This study was conducted to identify enzyme systems eventually catalysing a local cerebral metabolism of citalopram, a widely used antidepressant of the selective serotonin reuptake inhibitor type. The metabolism of citalopram, of its enantiomers and demethylated metabolites was investigated in rat brain microsomes and in rat and human brain mitochondria. No cytochrome P-450 mediated transformation was observed in rat brain. By analysing H 2 O 2 formation, monoamine oxidase A activity in rat brain mitochondria could be measured. In rat whole brain and in human frontal cortex, putamen, cerebellum and white matter of five brains monoamine oxidase activity was determined by the stereoselective measurement of the production of citalopram propionate. All substrates were metabolised by both forms of MAO, except in rat brain, where monoamine oxidase B activity could not be detected. Apparent K m and V max of S-citalopram biotransformation in human frontal cortex by monoamine oxidase B were found to be 266 M and 6.0 pmol min −1 mg −1 protein and by monoamine oxidase A 856 M and 6.4 pmol min −1 mg −1 protein, respectively. These K m values are in the same range as those for serotonin and dopamine metabolism by monoamine oxidases. Thus, the biotransformation of citalopram in the rat and human brain occurs mainly through monoamine oxidases and not, as in the liver, through cytochrome P-450.

show abstract

Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”*

Dingemanse

Wallnöfer

Gieschke

et al. 1998

Clin Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Safety and tolerability of combined treatment with moclobemide and SSRIs: a preliminary study of 19 patients

Cited by 5 publications

References 17 publications

Potential Roles of microRNAs in the Regulation of Monoamine Oxidase A in the Brain

Potential Roles of microRNAs in the Regulation of Monoamine Oxidase A in the Brain

In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations

Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”*

Contact Info

Product

Resources

About